Home » Newsletters » BioWorld Science

BioWorld Science

July 21, 2011

View Archived Issues

AstraZeneca divulges novel DAT and NET ligands

Suven Life Sciences' histamine H3 receptor antagonist reverses cognitive deficits in vivo

New irreversible epidermal growth factor receptor inhibitor shows preclinical antitumor activity

Sanofi claims new tryptase beta inhibitors

Galderma discloses novel androgen receptor antagonists

Chinese university presents new antitumor noscapine derivatives

Bayer Schering Pharma patents novel apoptosis imaging agents

Idenix identifies new anti-HCV agents

Phase IV data presented on maraviroc in pediatric patients with CCR5-tropic HIV-1 infection

Results presented from first trial evaluating DNA vaccine for HIV in children

GABA(A) receptor inverse agonist exhibits procognitive effects in vivo

Pfizer signs agreement to acquire Icagen

AMAG Pharmaceuticals and Allos Therapeutics advance plans to merge

Valeant enters into agreement for Canadian marketing and distribution rights to Zuacta

Dynavax reports topline phase III data on Heplisav versus Engerix-B

Pharmasset announces new data from phase IIb PSI-7977 trial

FDA clears trial of intranasal Ampligen with seasonal influenza vaccine

FDA places clinical hold on phase II IMO-3100 trial

MundiPharma to launch Norspan tape in Japan in August

SuperGen acquires Astex Therapeutics

Japanese Lexapro launch scheduled for next month

AstraZeneca's Brilinta approved in U.S.

Taiho and Nordic Group to collaborate on Teysuno

First patient enrolled in NCI's pediatric phase I trial of Marqibo

Single-vial Taxotere formulation launched in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
Medline raises $6.3B in fourth med-tech IPO of December
BioWorld MedTech
Medline Inc. returned to the public markets with a blockbuster IPO of $6.26 billion, reportedly this year’s largest IPO globally. The upsized offering of more...
Vitesse finesse pays off: DBV wins in peanut allergy phase III
BioWorld
DBV Technologies SA’s pivotal phase III trial with the Viaskin Peanut allergy patch came through for the company, and officials plan a BLA filing with the U.S....
Acryl raises $28M IPO, aiming to bridge medical divide with AI
BioWorld MedTech
Acryl Inc. debuted on South Korea’s Kosdaq Dec. 16, raising ₩42.12 billion ($28.5 million) in an IPO. Shares (KOSDAQ:0007C0) closed at ₩67,000 on the first day,...